BiOpticROCO:6850 92 FCF Margin % is 42.87% as of Dec. 2025, which is 297% above its 10-year median of 10.79. GuruFocus rates ROCO:6850 with a GF Score™ of 92/100 and a GF Value™ of NT$44.89 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 958 Biotechnology companies, BiOptic ranks better than 94.57% on this metric.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. BiOptic's Free Cash Flow for the
six
months ended in Dec. 2025 was NT$55.3 Mil. BiOptic's Revenue for the
six
months ended in Dec. 2025 was NT$129.0 Mil. Therefore, BiOptic's FCF Margin % for the quarter that ended in Dec. 2025 was 42.87%.
The historical rank and industry rank for BiOptic's FCF Margin % or its related term are showing as below:
ROCO:6850'
s FCF Margin % Range Over the Past 10 Years
Min: -216.67 Med: 10.79 Max: 36.76
Current: 36.76
During the past 8 years, the highest FCF Margin % of BiOptic was 36.76%. The lowest was -216.67%. And the median was 10.79%.
ROCO:6850's FCF Margin % is ranked better than 94.57% of 958
companies
in the Biotechnology industry
Industry Median: -85.21
vs ROCO:6850: 36.76
BiOptic FCF Margin % Related Terms
BiOptic FCF Margin % Historical Data
* Premium members only.
The historical data trend for BiOptic's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6850 vs VRTX, REGN, ALNY: FCF Margin % Comparison
For the Biotechnology subindustry, BiOptic's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BiOptic FCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BiOptic's FCF Margin % distribution charts can be found below:
* The bar in red indicates where BiOptic's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BiOptic (ROCO:6850) has a FCF Margin % of 42.87% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on BiOptic and its competitors. This is 297% above median its historical median of 10.79. According to the industry distribution chart, BiOptic ranks #52 out of 958 companies in the Biotechnology industry, placing it in the top 5.4%.
Is BiOptic's FCF Margin % too high?
BiOptic's current FCF Margin % of 42.87% is 297% above median its 10-year median of 10.79. Based on the distribution chart, BiOptic ranks #52 out of 958 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, BiOptic has a GF Score™ of 92/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BiOptic's FCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, BiOptic ranks #52 out of 958 companies for FCF Margin %. This places BiOptic in the top 5% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on BiOptic and its competitors. BiOptic's current FCF Margin % is 42.87%, which is 297% above median its own 10-year median of 10.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BiOptic stock overvalued right now?
Based on GuruFocus' analysis, BiOptic (ROCO:6850) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$44.89, compared to a current price of NT$34.40 — trading 23.4% below its estimated fair value. The current FCF Margin % is 42.87%, which is 297% above median its 10-year median of 10.79. BiOptic's overall GF Score™ is 92/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For BiOptic (ROCO:6850), the current FCF Margin % is 42.87% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BiOptic (ROCO:6850) Overvalued in 2026?
Based on GuruFocus' analysis, BiOptic stock appears to be undervalued.
The current stock price of NT$34.40 is trading 23.4% below its estimated GF Value™ of NT$44.89.
GuruFocus considers BiOptic to be Modestly Undervalued.
Key valuation signals for ROCO:6850:
FCF Margin %: 42.87% (297% above median its 10-year median of 10.79)
GF Value™: NT$44.89 vs. price of NT$34.40 (23.4% below fair value)
No single metric tells the full story. See the ROCO:6850 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BiOptic Inc is a biotechnology instrumentation company that develops scientific products for research and clinical applications. It serves professionals and laboratories dedicated to life science research, clinical diagnostics, pharmaceutical and food industries, animal husbandry, and agriculture, performing diagnostic molecular genetic analyses.
92GF Score
Get the complete analysis for ROCO:6850
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6850 has been successfully added to your 
